Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Current Assets (2016 - 2025)

AC Immune (ACIU) has disclosed Current Assets for 9 consecutive years, with $196.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Current Assets rose 39.15% to $196.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $196.3 million, a 39.15% increase, with the full-year FY2024 number at $196.3 million, up 40.89% from a year prior.
  • Current Assets was $196.3 million for Q4 2024 at AC Immune, up from $141.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $256.4 million in Q4 2020 to a low of $133.0 million in Q4 2022.
  • A 5-year average of $189.3 million and a median of $196.3 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: plummeted 39.49% in 2022, then skyrocketed 39.15% in 2024.
  • AC Immune's Current Assets stood at $256.4 million in 2020, then fell by 14.28% to $219.8 million in 2021, then tumbled by 39.49% to $133.0 million in 2022, then grew by 6.11% to $141.1 million in 2023, then surged by 39.15% to $196.3 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Current Assets are $196.3 million (Q4 2024), $141.1 million (Q4 2023), and $133.0 million (Q4 2022).